Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.

Latest Post

April 03, 2020

Generic Drugs in China – Understanding the Regulatory Landscape

With the continuous progress in medical science and technology, drug evaluation criteria in China are also changing and improving. In the past, drug evaluation criteria did not require generic drugs to have the consistent quality and efficacy of innovator drugs; so some had a gap in efficacy. Since 2015, the National Medical Products Administration of China (NMPA), formerly the China Food and Drug Administration (CFDA), rolled out the Generic Quality and Efficacy Consistency Evaluation (GQEC) to improve the quality and efficacy of generic drugs. Generic drugs whose quality and efficacy are deemed equivalent to innovator drugs will enjoy preferential treatment in public hospitals and prescriptions.
Lynn Yao

Lynn Yao

Manager, Scientific Affairs, China


Search the Blog





  • Previous Posts
    Daniel Bantz and Jen Riter present on Performance Testing

    May 29, 2018

    West Experts to Present on Performance Testing - June 18

    Caitlin Storbeck

    Caitlin Storbeck

    Specialist, Global Communications